In a recent episode of the ‘Bell2Bell Podcast’ hosted by Stuart Smith, Astiva Health was spotlighted as a significant player in the Medicare Advantage Prescription Drug (“MAPD”) sector. The episode featured an exclusive interview with Astiva Health’s Co-Founder and CEO, Dr. Tri Nguyen, a renowned expert in internal medicine and cardiology.
Listen to the full interview to hear Dr. Nguyen discuss Astiva Health’s journey since its inception in 2020 and its expansion plans. He shared insightful details about the company’s expansion to Los Angeles, San Bernardino, and Riverside from January 1, 2024, marking a pivotal phase in transforming healthcare delivery.
One key highlight from the podcast was Astiva Health surpassing the 10,000-member milestone. Dr. Nguyen attributed this success to the company’s philosophy, which emphasizes loving life at any age. This principle is central to Astiva’s commitment to ensuring life is lived with fulfillment.
Astiva Health’s approach goes beyond providing medical care and prescription drugs. As Dr. Nguyen explains in the interview, it includes offering rich supplemental benefits to engage enrollees in a meaningful, healthy life. He emphasized the importance of patient involvement in successful medical outcomes, a cornerstone of Astiva Health’s strategy.
Looking forward in the podcast discussion, Dr. Nguyen outlined Astiva Health’s operational goals for 2024, including an ambitious plan to list its common shares on the NASDAQ Global Select. This strategic move aligns with Astiva Health’s broader goals of expanding its impact.
The vision for Astiva Health, as Dr. Nguyen shares on the Bell2Bell Podcast, is to redefine healthcare accessibility and quality. He envisions Astiva Health as a comprehensive healthcare provider for all who can benefit from it, highlighting potential growth and service expansion.
The interview concluded with Dr. Nguyen thanking Stuart Smith for the opportunity to discuss Astiva Health’s journey and future plans. For more information about Astiva Health, listeners are directed to the company’s website.
Catch the full depth of this engaging conversation with Dr. Tri Nguyen on the Bell2Bell Podcast, offering listeners a deeper understanding of Astiva Health’s mission, achievements, and future aspirations in the healthcare sector.
For more information, visit the company’s website at www.AstivaHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Aggressive repurchase of its own stock by Earth Science Tech, a growing holding company focused…
Last year, Congress passed changes to Medicaid eligibility requirements and CMS was given a deadline to issue…
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The…
Cardiovascular disease remains one of the most expensive health conditions in the United States. Cardio…
The FIFA World Cup started on June 11 and will end on July 19. 48…
A study conducted by a team at Mass General Brigham has found that people with…